Outstanding Recoveries
- Home
- Outstanding Recoveries
Verdicts & Settlements
Since Milberg’s founding in 1965, the firm has recovered more than $50 billion for our clients while prompting meaningful changes in corporate governance.
Filter By
Select Practice Area
-
See More$100 Million Settlement – Chase Bank USA, N.A. “Check Loan” Contract Litigation
In re Chase Bank USA, N.A. “Check Loan” Contract Litig., No. 09-2032 (N.D. Cal.)Milberg served on the Executive Committee representing the class in this action against JP Morgan Chase & Co. The complaint alleged that Chase improperly increased by 150% the minimum monthly payment required for customers who entered into balance transfer loans with “fixed” interest rates that were guaranteed to remain so for the “life of the loan.” Milberg and its Co-Counsel achieved a $100 million settlement for the class. -
See More$54 Million Settlement – Miller v. CareCore National LLC
U.S. ex rel. Miller v. CareCore National LLC et al., No. 13-1177 (S.D.N.Y)Milberg, along with Co-Counsel, represented a whistleblower or “relator” in a false claims act case against CareCore, a company that provides benefit management services to Medicare Advantage and Medicaid Managed Care Organizations. The relator alleged that CareCore violated the False Claims Act by approving “prior authorizations” for expensive diagnostic procedures (such as MRIs) without reviewing them for medical necessity, as required. The Government intervened and the case settled in May 2017 for $54 million and the relator’s share of the settlement was $10.5 million. -
See MoreTrump Hotels Shareholder Derivative Litigation
In re Trump Hotels Shareholder Derivative Litigation, No. 96-7820 (S.D.N.Y.)The plaintiff shareholders asserted various derivative claims on behalf of the company against certain Trump entities and senior Trump executives in connection with the sale of a casino to a company in which the plaintiffs owned stock. Milberg negotiated a settlement requiring the company to increase the number of directors and the review of certain future transactions by a special committee. -
See More$138 Million Settlement – Biovail Corp. Securities Litigation
In re Biovail Corp. Securities Litigation, No. 03-8917 (S.D.N.Y.)Milberg, representing Local 282 Welfare Trust Fund and serving as Co-Lead Counsel, litigated this securities action alleging that defendants made misleading statements concerning Biovail’s financial results and its drug, Cardizem LA. Following substantial discovery, including depositions across the U.S. and Canada, Milberg obtained a $138 million settlement for the class, and Biovail agreed to institute significant corporate governance changes. -
See More$75 Million Settlement – Irvine v. ImClone Systems, Inc.
Irvine v. ImClone Systems, Inc., No. 02-0109 (S.D.N.Y.)Milberg served as Co-Lead Counsel in this case, in which the plaintiffs alleged that ImClone misrepresented the likelihood that its drug, Erbitux, would be approved, thereby artificially inflating the price of ImClone stock. The court approved a $75 million cash settlement in 2005.
